Comparing Glaukos (GKOS) and Atrion (ATRI)

Glaukos (NYSE:GKOS) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Glaukos and Atrion, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Glaukos 0 3 5 0 2.63
Atrion 0 0 0 0 N/A



Glaukos currently has a consensus target price of $71.38, suggesting a potential upside of 3.30%. Given Glaukos’ higher possible upside, research analysts clearly believe Glaukos is more favorable than Atrion.

Dividends

Atrion pays an annual dividend of $5.40 per share and has a dividend yield of 0.6%. Glaukos does not pay a dividend. Atrion has raised its dividend for 16 consecutive years.

Insider and Institutional Ownership

98.6% of Glaukos shares are held by institutional investors. Comparatively, 61.5% of Atrion shares are held by institutional investors. 8.7% of Glaukos shares are held by insiders. Comparatively, 22.1% of Atrion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Glaukos and Atrion’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Glaukos -5.93% -7.15% -6.11%
Atrion 22.76% 16.89% 15.30%

Earnings & Valuation

This table compares Glaukos and Atrion’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Glaukos $181.28 million 13.87 -$12.95 million ($0.37) -186.76
Atrion $152.45 million 10.71 $34.26 million N/A N/A

Atrion has lower revenue, but higher earnings than Glaukos.

Volatility & Risk

Glaukos has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Atrion has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.

Summary

Atrion beats Glaukos on 8 of the 14 factors compared between the two stocks.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The company's product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States and other 16 countries, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise MPS2 Myocardial Protection System that delivers fluids and medications, mixes critical drugs, and controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.